Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Plos Pathogens|July 31, 2015
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene ExpressionGilles Darcis, Anna Kula, Sophie Bouchat, et al.
BMJ Open|August 28, 2023
Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trialSharana Mahomed, Nigel Garrett, Disebo Potloane, et al.
Frontiers in Immunology|December 30, 2022
Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settingsKristin L Boswell, Timothy A Watkins, Evan M Cale, et al.
The Journal of Infectious Diseases|April 18, 2015
A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral LoadsKelly A Metcalf Pate, Christopher W Pohlmeyer, Victoria E Walker-Sperling, et al.
The Lancet. HIV|October 6, 2023
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trialMagdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, et al.
The Journal of Infectious Diseases|September 25, 2021
Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent VorinostatCynthia L Gay, Katherine S James, Marina Tuyishime, et al.
Nature Medicine|September 12, 2024
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trialBoris Julg, Victoria E K Walker-Sperling, Kshitij Wagh, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 2020
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibodyMangaiarkarasi Asokan, Joana Dias, Cuiping Liu, et al.
Scientific Reports|October 26, 2022
Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half lifeBaoshan Zhang, Deepika Gollapudi, Jason Gorman, et al.
BMC Infectious Diseases|July 20, 2024
Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trialAmeena Goga, Trisha Ramraj, Logashvari Naidoo, et al.
Pageof 11